Theraclion in the news

Theraclion's revenue grew significantly in H1 2025 with reduced net loss and cash runway extended to August 2026, supporting ongoing development and research.

Theraclion's revenue grew significantly in H1 2025 with reduced net loss and cash runway extended to August 2026, supporting ongoing R&D and commercial efforts.

Theraclion advanced regulatory approvals and commercial rollout of its non-invasive Sonovein® HIFU varicose vein treatment, boosting revenue and reducing losses in H1 2025.

Theraclion's revenue grew significantly in H1 2025 with reduced net loss and cash runway extended to August 2026, supporting ongoing development and research.

Theraclion reported strong clinical results, regulatory certifications in Europe and China, significant revenue growth, and plans for U.S. market entry in 2026.

Theraclion advanced its non-invasive ultrasound varicose vein treatment with successful US trial results, regulatory approvals in Europe and China, strong revenue growth, and expanded commercial efforts.

Sonovein device received key Chinese safety certification, advancing Theraclion's market approval and expansion in China.

Theraclion's Sonovein® device achieved key Chinese safety certification, advancing its market entry for non-invasive varicose vein treatment in China.

Theraclion's Sonovein® device secured a crucial Chinese safety certification, paving the way for market entry in China.

Theraclion's Sonovein® ultrasound device achieved key Chinese safety certification, advancing its market entry in China.

Sonovein device received Chinese certification confirming compliance with medical electrical safety standards, advancing Theraclion's market entry in China.

Theraclion's US pivotal trial for its Sonovein HIFU device showed 96.8% vein closure at 12 months with excellent safety, supporting upcoming FDA submission.

Theraclion's US pivotal trial confirms its non-invasive HIFU device Sonovein is safe and effective for treating varicose veins, supporting upcoming FDA submission.

Theraclion's Sonovein device for non-invasive varicose vein treatment received strict EU MDR certification, confirming regulatory compliance and quality.

Theraclion secured EU MDR certification for its Sonovein device, ensuring regulatory compliance and boosting its commercial prospects in Europe.

Theraclion's Sonovein device and quality system received EU MDR certification for non-invasive varicose vein treatment.

Theraclion's Sonovein device for non-invasive varicose vein treatment received strict EU MDR certification.

Theraclion's Sonovein® device for non-invasive varicose vein treatment received EU MDR certification, enhancing its commercial prospects and regulatory compliance.

Theraclion's Sonovein® received EU MDR certification, enhancing its market access and commercial potential for non-invasive varicose vein treatment.

Theraclion's non-invasive Sonovein® ultrasound treatment for varicose veins showed 96.8% efficacy and strong safety in a US pivotal trial, supporting FDA submission.